Trade Ionis Pharmaceuticals, Inc. - IONS CFD

37.58
2.79%
0.07
Low: 36.3
High: 37.59

Mon - Fri: 13:30 - 20:00

Ionis Pharmaceuticals live chart

Trading Conditions
Long position overnight fee
-0.0225%
Short position overnight fee
-0.0219%
Overnight fee time
21:00 (UTC)
Min traded quantity
1
Currency
USD
Margin
20%
Stock exchange
United States of America
Commission on trade
0%
Content 2
Content 2
Content 2

Key Stats

Prev. Close* 36.56
Open* 36.3
Day's Range* 36.3 - 36.3
1-Year Change* 2.34%
Volume N/A
Average Vol. (3m) 23.1621
52 wk Range N/A
Market Cap 5196.89
P/E Ratio N/A
Shares Outstanding 141.8M
Revenue 840.768
EPS -0.02761
Dividend (Yield %) N/A
Beta 0.76291
Next Earnings Date Aug 2, 2022
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Ionis Pharmaceuticals Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry: Biotechnology & Medical Research (NEC)

2855 Gazelle Ct
CARLSBAD
CALIFORNIA 92010
US

People Also Watch

US Natural Gas Spot

8.70 Price
-1.270% 1D Chg, %
Long position overnight fee -0.0010%
Short position overnight fee -0.0125%
Overnight fee time 21:00 (UTC)
Spread 0.020

Market analysis

Ionis Pharmaceuticals, Inc. (IONS) is up 3.02% on Friday: What You Should Know

Ionis Pharmaceuticals, Inc. (IONS) stock is up 3.02% in the last day. For details on what happened in the market, see our analysis.

07:00, 28 May 2022

Learn more about

Still looking for a broker you can trust?


Join the 380.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account

2. Make your first deposit

3. You’re all set. Start trading